Search results
Results from the WOW.Com Content Network
Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder characterized by a group of symptoms that commonly include abdominal pain, abdominal bloating and changes in the consistency of bowel movements. [1] These symptoms may occur over a long time, sometimes for years. [2]
For premium support please call: 800-290-4726 more ways to reach us
Vitamin D treatment may be associated with less inflammatory bowel disease reoccurrence of symptoms (relapse). It is not clear if this treatment improves the person's quality of life or what the clinical response to vitamin D treatment. The ideal treatment regime and dose of vitamin D therapy has not been well enough studied. [90]
The preferred treatment in those with mild to moderate dehydration is oral rehydration therapy (ORT). [24] For children at risk of dehydration from vomiting, taking a single dose of the anti vomiting medication metoclopramide or ondansetron , may be helpful, [ 55 ] and butylscopolamine is useful in treating abdominal pain .
Food and Drug Administration approvable letter - a quasi-approval for a drug/medical device issued by the FDA up until 2008 that required further data before full approval could occur; God committee (currently a redirect to a section of death panel) - medical-ethics committee created to allocate dialysis treatment
The anti-TNF-α monoclonal antibody infliximab is a major biological therapy for inflammatory bowel diseaseBiological therapy, the use of medications called biopharmaceuticals or biologics that are tailored to specifically target an immune or genetic mediator of disease, plays a major role in the treatment of inflammatory bowel disease. [1]
Irritable bowel syndrome is a result of stress and chronic activation of the HPA axis; its symptoms include abdominal pain, changes in bowel movements, and an increase in proinflammatory cytokines. Overall, studies have found that the luminal and mucosal microbiota are changed in irritable bowel syndrome individuals, and these changes can ...
Robert H. Lustig (born 1957) is an American pediatric endocrinologist.He is professor emeritus of pediatrics in the division of endocrinology at the University of California, San Francisco (UCSF), where he specialized in neuroendocrinology and childhood obesity.